Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 15;16(1):8.
doi: 10.1186/s13024-021-00429-4.

Remodeling Alzheimer-amyloidosis models by seeding

Affiliations
Review

Remodeling Alzheimer-amyloidosis models by seeding

Brittany S Ulm et al. Mol Neurodegener. .

Abstract

Alzheimer's disease (AD) is among the most prevalent neurodegenerative diseases, with brain pathology defined by extracellular amyloid beta deposits and intracellular tau aggregates. To aid in research efforts to improve understanding of this disease, transgenic murine models have been developed that replicate aspects of AD pathology. Familial AD is associated with mutations in the amyloid precursor protein and in the presenilins (associated with amyloidosis); transgenic amyloid models feature one or more of these mutant genes. Recent advances in seeding methods provide a means to alter the morphology of resultant amyloid deposits and the age that pathology develops. In this review, we discuss the variety of factors that influence the seeding of amyloid beta pathology, including the source of seed, the time interval after seeding, the nature of the transgenic host, and the preparation of the seeding inoculum.

Keywords: Alzheimer’s disease; Amyloid-β; Mouse models; Prion disease; Seeding.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1–13. doi: 10.1016/j.jalz.2011.10.007. - DOI - PMC - PubMed
    1. Jankowsky JL, Zheng H. Practical considerations for choosing a mouse model of Alzheimer’s disease. Mol Neurodegener. 2017;12:89. doi: 10.1186/s13024-017-0231-7. - DOI - PMC - PubMed
    1. Liu P, Reichl JH, Rao ER, McNellis BM, Huang ES, Hemmy LS, et al. Quantitative comparison of dense-Core amyloid plaque accumulation in amyloid-β protein precursor transgenic mice. J Alzheimers Dis. 2017;56:743–761. doi: 10.3233/JAD-161027. - DOI - PMC - PubMed
    1. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, et al. Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci. 2000;20:3606–3611. doi: 10.1523/JNEUROSCI.20-10-03606.2000. - DOI - PMC - PubMed
    1. Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ. Exogenous induction of cerebral β-amyloidosis in βAPP-transgenic mice. Peptides. 2002;23:1241–1247. doi: 10.1016/S0196-9781(02)00059-1. - DOI - PubMed

Publication types

Substances